#biotech
Latest news and interesting information about biotech.
Japan and US Allocate $1 Billion for AI Research
The US and Japan commit $1 billion over five years to advance AI research, covering biotechnology, quantum science, and more.
Legend Biotech Buy Rating Reiterated
H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.
Mineralys Presents Lorundrostat Data in Kidney Patients
Mineralys (MLYS) reveals new clinical data for lorundrostat showing efficacy in hypertensive patients with chronic kidney disease.
Norway stocks rise at close
Norway stocks closed higher Thursday; Oslo OBX up 0.33%. Gainers: Kongsberg Gruppen, TGS NOPEC, Subsea 7. Losers: Hafnia, Frontline, Hoegh Autoliners.
Barclays Starts Oncology Biotechs with Positive Outlook
Barclays initiates coverage of Alpha Tau Medical, Cellectis, Immunome, and Sutro Biopharma with Overweight ratings.
Medicus Pharma secures up to $22M financing facility
Medicus Pharma secures up to $22M in structured financing. The biotech firm gets $12M immediate capital and $10M milestone-based funds.
Small biotech firms latch onto AI faster
Alex Ng, President of Tencent Healthcare, says small biotech firms adopt AI faster than big ones, boosting efficiency and cutting costs.
Junshi Biosciences completes phase III lung cancer study
Junshi Biosciences completes phase III lung cancer study. Toripalimab combination shows promising results in resectable stage II-III NSCLC.
Morgan Stanley Initiates Avalyn Pharma with Overweight
Morgan Stanley initiates Avalyn Pharma with Overweight rating and $53 target. The inhaled therapies AP01 and AP02 show promise in pulmonary fibrosis.
Goldman Sachs Backs Seaport Stock
Goldman Sachs initiates coverage on Seaport Therapeutics with an Early-Stage Biotech rating. Learn about the company's platform and financials.
Benitec Biopharma gene therapy stock shows clinical promise
Benitec Biopharma gene therapy stock shows clinical promise. BB-301 achieves 100% response rate in OPMD. Analysis on Bond.az.
Kura Oncology SWOT Analysis: Launch Test
Kura Oncology SWOT analysis: FDA approval, early sales results, and future prospects for this biotech stock.
ARE faces biotech headwinds
ARE faces biotech headwinds. The company cuts dividends, restructures its portfolio, and makes strategic changes to navigate industry challenges.
Ionis Stock Gains on FDA Approval
Ionis Pharmaceuticals stock gains momentum following FDA approval of REDEMPLO. Financials, pipeline, and growth prospects analyzed.
Cytokinetics SWOT Analysis: Profit Test
Cytokinetics SWOT analysis: biotech stock faces profitability test. Aficamten approval, financial health, and market outlook.
ARK Buys Cerebras Stock, Sells AMD
Cathie Wood's ARK ETF buys Cerebras, Twist Bioscience, and Bullish; sells AMD. Focus on tech and biotech sectors.
HCW Biologics Raises $4M in Private Placement
HCW Biologics completes $4M private placement. Stock surges 112% in a week. E.F. Hutton acted as agent.
Cantor Reiterates Overweight on ORIC Stock
Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.
Assembly Biosciences prices $100M stock offering at $26.50
Assembly Biosciences prices $100 million stock offering at $26.50 per share. Gilead Sciences among investors. Proceeds for clinical development.
Kura Oncology SWOT: Biotech Stock Faces Launch Test
Kura Oncology SWOT analysis: Komzifti launch, financials, analyst ratings, and investment risks covered in detail.
VIR stock gains momentum on partnership and clinical progress
SWOT analysis of Vir Biotechnology: Astellas partnership, VIR-5500 and Hepatitis Delta program progress boost stock. Read on Bond.az.
Belite Bio Stock Rises on NDA Progress
Belite Bio stock rises as H.C. Wainwright reiterates Buy rating and NDA progresses. Tinlarebant potential FDA approval expected in Q1 2027.
Syndax stock gains momentum on strong launch
Syndax Pharmaceuticals stock gains momentum with strong Revuforj launch. Learn about financial performance, pipeline, and market outlook.
Adaptive Biotechnologies CFO Sells $40,619 in Stock
Adaptive Biotechnologies CFO Kyle Piskel sold $40,619 worth of stock to cover tax obligations from RSU vesting.
Biotech at Inflection Point: JPMorgan Covers 14 Firms | Bond.az
JPMorgan covers 14 biotech firms at inflection point, with ratings and price targets. See which companies are poised for growth and the catalysts ahead.
Roivant Sciences stock hits all-time high of $30.35
Roivant Sciences stock hits all-time high of $30.35. The biotech firm surged 156% in a year and beat EPS estimates.
Jupiter Stock Surges on MDMA Therapy Deal
Jupiter Neurosciences stock surges 75.9% on MDMA therapy licensing deal. ALA-002 is a next-generation formulation.
Traws Pharma Gets $8 Price Target from H.C. Wainwright
H.C. Wainwright reaffirms Buy on Traws Pharma with $8 target. Financing secured for influenza drug trial. Read more on Bond.az.
Jefferies Initiates SAB Biotherapeutics with Buy
Jefferies initiates coverage on SAB Biotherapeutics with a Buy rating and $11 target, focusing on SAB-142 diabetes therapy.
RTW Biotech Sets June 11 Annual Meeting
RTW Biotech Opportunities Ltd sets its annual general meeting for June 11, 2026. Details on proxy voting and shareholder information.
...